Ahmed Bedair

Consultant Clinical Oncologist

[Ahmed Bedair @ahmedonc]

Excellent review

[CA: A Cancer Journal for Clinicians @CACancerJournal]

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key.

New #OpenAccess review by Andratschke et al:
https://t.co/T41ik4rEsa

@OncoAlert #RadOnc

[RTTQA @RTTQA_UK]

Want to be part of shaping the future direction of RT research in the UK? An exciting opportunity has arisen to work as a research fellow within the @NIHR RTTQA Group, based at Mount Vernon Cancer Centre.
For more info please DM us! #radonc #rtqa

https://t.co/gY7UU7PwPl

[Ahmed Bedair @ahmedonc]

Thought provoking!

[Stephen V Liu, MD @StephenVLiu]

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

[David Sher @DavidSherMD]

This paper is absolutely fantastic.

It is essentially the Bible for NPC CTV delineation.

Incredible contribution to the field!

https://t.co/YIkrYLSTrD

[Pierre Blanchard, MD @PBlanchardMD]

10y results of FAST FORWARD (adjuvant #breastcancer RT) trial presented at #ESTRO25 by AM Brunt.

Compared to 40Gy/15, 26Gy/5:
1. Non inf for IBR (even superior?)
2. Similar recurrence free interval, breast cancer interval, OS
3. No diff in PRO or toxicity

Clearly 26/5 SOC for

[Pierre Blanchard, MD @PBlanchardMD]

🚨10y results of HYPO RT PC at #ESTRO25

Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT
1. Non inferior for FFS (even better?)
2. Similar bPFS, DMFS, ADT use, OS
3. Similar GU/GI tox (except transient flare at 1y for UHF)

[David Sher @DavidSherMD]

Incredible study on HNSCC ENI now published in @JCO_ASCO

Randomized-controlled trial on ENI dose de-escalation

Nominal dose 50 Gy vs. 43 Gy in 34 fractions

EQD2 44 Gy vs 34 Gy

6 fractions per week, **NO CHEMOTHERAPY**

https://t.co/5yMiGPqfKS

[Ahmed Bedair @ahmedonc]

Special thanks for our colleagues from Clattebridge Cancer Centre and the Christie @CobbenDavid @Abutalebmk who made a special appearance in the Autumn Scientific meeting of Northern Ireland Society of Oncology.
@CCCNHS

[Ahmed Bedair @ahmedonc]

@WesternHSCTrust @NICCBeamTeam @BelfastTrust @hosamrgb @UnaCardin

[Ahmed Bedair @ahmedonc]

Northern Ireland Society of Oncology (NISO) Autumn scientific meeting. A wonderful afternoon with colleagues from all over Northern Ireland. Lovely updates with a bit of humour. #NWCC #NISO #NICC #westernHSCTrust

[Ahmed Bedair @ahmedonc]

Northern Ireland Society of Oncology (NISO) Autumn scientific meeting. A wonderful afternoon with colleagues from all over Northern Ireland. Lovely updates with a bit of humour. #NWCC #NISO #NICC #westernHSCTrust

[Ahmed Bedair @ahmedonc]

@martingkelly Brilliant song

[Tom Newsom-Davis @tnewsomdavis]

Osimertinib use associated with nutritional deficiencies

❗️Significant deficiencies of Vit B, Vit D, Iron, Vit B12

❓May reflect GI side effects of drug

🤔 Should screen for these during Osimertinib treatment: quick and cheap to do

#ASCO24 #LCSM

[Myriam Chalabi @MyriamChalabi]

TRANSMET: CT+liver transplant vs CT alone in pts with
unresectable CRC liver mets
- 94 pts
- ⁠5-year OS in ITT: 57% in CT+LT vs 13% in CT arm (HR 0.37,p=0.0003)
- 74% of transplanted pts had recurrences in one or more organs.
- anybody else feeling like🤯🤯🤯🤯?
#ASCO24

[Oncology Brothers @OncBrothers]

Day 1 #ASCO24 Highlights:

1. #CROWN: Lorlatinib in ALK mNSCLC

2. #PALOMA3: SC #Amivantamab in EGFR mNSCLS

3. #MARIPOSA: Ami in EGFR mNSCLC

4. #GlobalOncCoP @inas_md

5. #SocialMedia: Leveraging this @fumikochino @lungoncdoc

#OncTwitter #MedEd #MedTwitter @ASCO #lcsm

1/6

[Shankar Siva @_ShankarSiva]

📢🚨#ASCO24 plenary @DavidRSpigel - pivotal ADRIATIC ph III trial; adjuvant durvalumab arm after chemoradiotherapy (cCRT) ± PCI in small cell #lungcancer; ⬆️ OS (HR 0.73), median OS 55.9 vs 33.4 for placebo. Grade 3/4 AEs in 24.3% vs 24.2%. 💥Practice changing!!! #radonc #lcsm

[Patrick Forde @FordePatrick]

The new standard of care is consolidation immunotherapy for limited stage small cell lung cancer & the first systemic therapy advance for limited small cell in ~50yrs. Allied to Laura we had fun on the @ASCO non-metastatic NSCLC/SCLC/meso track committee this year! #lcsm #ASCO24

[Patrick Forde @FordePatrick]

Impressive increase in PFS with consolidation osimertinib after CRT for pts w unresectable stage III lung cancer. Crossover on progression 82% higher than in most other studies. OS far from mature. Will be adopted as a new standard where it is available I believe. #lcsm #ASCO24

[Corinne Faivre-Finn @finn_corinne]

Consensus guidelines on the diagnosis and management of RT pneumonitis
▶️ Delphi consensus
▶️Practical guide to assess risk in individual patients
▶️unmet need-> clarify the relationship between RT-drug-induced pneumonitis + optimal management strategies
https://t.co/PXFmMuLLjl

[Ahmed Bedair @ahmedonc]

@KLCRFD @NICCBeamTeam @JolyneOHare @cbcrockett87 @ktumelty87 Well deserved 😍

[Matthias Guckenberger @Mat_Guc]

First prospective data of SBRT for early stage NSCLC in pts with interstitial lung disease
👉 risk of treatment-related mortality 7.7%
👉 median OS 25mo
👍 prespecified acceptability thresholds for toxicity & efficacy met
👏 @drdavidpalma and colleagues
https://t.co/aaBsUwLecu